Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus<SUBTITLE>Progressive Requirement for Multiple Therapies (UKPDS 49)</SUBTITLE>
JAMAPublished 2 June 1999
Robert C. Turner
Citations2,364
SJR quartileQ1
SJR score5.35
SNIP10.71
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The proportion of patients who maintained target glycemic levels declined markedly over 9 years of follow-up, and the progressive deterioration of diabetes control was such that after 3 years approximately 50% of patients could attain this goal with monotherapy, and by 9 years this declined to approximately 25%.
Abstract
Each therapeutic agent, as monotherapy, increased 2- to 3-fold the proportion of patients who attained HbA1c below 7% compared with diet alone. However, the progressive deterioration of diabetes control was such that after 3 years approximately 50% of patients could attain this goal with monotherapy, and by 9 years this declined to approximately 25%. The majority of patients need multiple therapies to attain these glycemic target levels in the longer term.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
The LancetIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
20,069 Citations1998
The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Diabetes Research and Clinical PracticeIntensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study
3,104 Citations1995Yasuo Ohkubo, Hideki Kishikawa +7 more
In conclusion, intensive glycemic control by multiple insulin injection therapy can delay the onset and the progression of diabetic retinopathy, nephropathy and neuropathy in Japanese patients with NIDDM.
BMJComparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes
488 Citations1994David McCane, Robert L. Hanson +5 more
It is suggested that determination of glycated haemoglobin or fasting plasma glucose concentrations alone may be acceptable alternatives to measuring glucose concentration two hours after challenge with 75 g glucose for the diagnosis of diabetes.
Annals of Internal MedicineUnited Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications in Non-Insulin-dependent Diabetes Mellitus
467 Citations1996Robert G. Turner, Carole Cull +2 more
The prospective data in patients with NIDDM suggest that hyperglycemia is a risk factor for cardiovascular disease, but insufficient data exist to determine whether there is a glycemic threshold for macrovascular disease.
DiabetesCardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM
366 Citations1997Mahmoud N. Ghazzi, Julio E. Pérez +6 more
Treatment with troglitazone appears to have a favorable impact on known cardiovascular risk factors and could potentially lower cardiovascular morbidity in NIDDM patients.
Diabetes CareVeterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): Results of the feasibility trial
357 Citations1995Carlos Abraira, John A. Colwell +9 more
Intense stepped insulin therapy in NIDDM patients who have failed glycemic control on pharmacological therapy is effective in maintaining near-normal gly glucose control for > 2 years without excessive severe hypoglycemia, weight gain, hypertension, or dyslipidemia.
Diabetes CareComparison of Fasting and 2-Hour Glucose and HbA1c Levels for Diagnosing Diabetes: Diagnostic criteria and performance revisited
330 Citations1997Michael M. Engelgau, Theodore J. Thompson +7 more
It is found that the current fasting diagnostic criterion favors specificity and the current 2-h criterion favors sensitivity and these results should prove valuable for defining the optimal tests and cutpoint values for diagnosing diabetes.
New England Journal of MedicineComparison of Insulin Regimens in Patients with Non-Insulin-Dependent Diabetes Mellitus
327 Citations1992Hannele Yki‐Järvinen, Marjut Kauppila +12 more
It is suggested that patients with NIDDM do not benefit from multiple insulin injections and that nocturnal insulin administration appears preferable to daytime administration, and glycemic control is improved in a manner similar to combination therapy with NPH insulin in the morning, a two-insulin-injection regimen, but induces less weight gain and hyperinsulinemia.
DiabetologiaTroglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients
239 Citations1996The Troglitazone study group, Sudhesh Kumar +9 more
It is concluded that troglitazone is effective and well-tolerated and shows potential as a new therapeutic agent for the treatment of NIDDM.
Diabetes CareIntensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trial
232 Citations1993Robert R. Henry, Barry Gumbiner +4 more
Intensive CIT, when combined with CBG measurements, can be used to rapidly improve glycemic control in type II diabetes without development of unacceptable hypoglycemia, however, this degree of metabolic improvement requires large doses of exogenous insulin to overcome peripheral insulin resistance and results in greater hyperinsulinemia with progressive weight gain.
Journal of Internal MedicineIntensified conventional insulin treatment retards the microvascular complications of insulin‐dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years
223 Citations1991Per Reichard, Bo Berglund +4 more
In conclusion, microvascular complications of diabetes were retarded by intensified conventional insulin treatment, however, such treatment increased the frequency of serious hypoglycaemia, and led to an increase in body weight.
JAMAStarting Insulin Therapy in Patients With Type 2 Diabetes
204 Citations1997Rodney A. Hayward
For patients with type 2 diabetes who were cared for by generalist physicians, starting insulin therapy was generally safe and effective in achieving moderate glycemic control in patients who initially had poor glycemic Control.
Diabetes CareComparison of Insulin With or Without Continuation of Oral Hypoglycemic Agents in the Treatment of Secondary Failure in NIDDM Patients
111 Citations1995Chun‐Chung Chow, Lynn W.W. Tsang +2 more
Both groups showed similar improvement of glycemie control but insulin requirements were very different, and both groups had significant improvement of fructosamine and glycosylated hemoglobin.
Diabetic MedicineThe Whitehall Study: Ten Year Follow‐up Report on Men With Impaired Glucose Tolerance With Reference to Worsening to Diabetes and Predictors of Death
96 Citations1984R. J. Jarrett, H. Keen +1 more
The major independent predictor of worsening was the baseline blood glucose level (glucose tolerance).
Diabetes CareSafety and Efficacy of Normalizing Fasting Glucose With Bedtime NPH Insulin Alone in NIDDM
72 Citations1995Kenneth Cusi, Glenn R. Cunningham +1 more
NPH insulin given at bedtime in amounts sufficient to achieve a normal FPG level does not cause excessive or severe hypoglycemia and does lead to good glycemic and lipid control in NIDDM.
DiabetologiaNIDDM: a rapid progressive disease Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment
28 Citations1996K. I. Birkeland, U Rishaug +2 more
In conclusion, insulin was more effective than glibenclamide treatment in obtaining control over hyperglycaemia in these patients, and once improved, glycaemic control did not deteriorate over 42 months in the insulin-treated group.
PubMedApproach to maintaining comparability of biochemical data during long-term clinical trials.
28 Citations1997C A Cull, Susan E. Manley +6 more
Diabetic MedicineOptimizing Blood Glucose Control in Type 2 Diabetes: an Approach Based on Fasting Blood Glucose Measurements
19 Citations1988Rury R. Holman, R. C. Turner
In older patients, where long‐term prevention of diabetic complications is not such an immediate priority, less strict blood glucose control may be reasonable, aiming to keep the fasting blood glucose values below 10 mmol l−1 in order to prevent symptoms secondary to glycosuria.